Farallon Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,800
| Closed | -$229K | – | 165 |
|
|
2024
Q2 | $229K | Sell |
4,800
-729,200
| -99% | -$34.8M | ﹤0.01% | 123 |
|
|
2024
Q1 | $31.8M | Sell |
734,000
-821,020
| -53% | -$35.6M | 0.14% | 59 |
|
|
2023
Q4 | $78.7M | Buy |
1,555,020
+828,020
| +114% | +$41.9M | 0.36% | 50 |
|
|
2023
Q3 | $33M | Buy |
727,000
+722,000
| +14,440% | +$32.7M | 0.15% | 67 |
|
|
2023
Q2 | $205K | Buy |
+5,000
| New | +$205K | ﹤0.01% | 135 |
|
|
2021
Q2 | – | Sell |
-630,500
| Closed | -$28.3M | – | 306 |
|
|
2021
Q1 | $28.3M | Sell |
630,500
-119,500
| -16% | -$5.37M | 0.14% | 89 |
|
|
2020
Q4 | $42.4M | Buy |
+750,000
| New | +$42.4M | 0.26% | 69 |
|
|
2018
Q1 | – | Sell |
-645,000
| Closed | -$32.4M | – | 94 |
|
|
2017
Q4 | $32.4M | Buy |
645,000
+195,000
| +43% | +$9.81M | 0.26% | 48 |
|
|
2017
Q3 | $22.8M | Buy |
+450,000
| New | +$22.8M | 0.2% | 52 |
|